Positive Data from Two Key MS Trials Added To Aubagio’s U.S. Label

The Food and Drug Administration (FDA) recently accepted the results from Genzyme’s TOWER and TOPIC  clinical trials, which assessed the safety and efficacy of oral, once-daily Aubagio® (teriflunomide) for Multiple Sclerosis, and will add the positive data to the product’s U.S. label. Genzyme is a leader in the development…

Revenge Star Madeleine Stowe is the New Face of Multiple Sclerosis

Featureflash / Shutterstock.com Television’s “Queen of Mean,” Revenge‘s Madeleine Stowe, recently opened up about her early memories of her father living with multiple sclerosis (MS), a progressive neurodegenerative disease that, until today, does not have a known cure. However, thanks to the efforts of countless researchers and MS…

Genzyme’s Aubagio, Lemtrada MS Therapies To Showcase at Conference

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) taking place in Boston between September 10th and 13th, Genzyme, a Sanofi company, will present its multiple sclerosis (MS) pipeline with a new group of trial treatments for early development of MS.